Genetic polymorphisms and their involvement in the regulation of the inflammatory response in asthma and COPD

Juan M. Reséndiz-Hernández1, 2, A–D, Ramcés Falfán-Valencia3, A–F

1 HLA Laboratory, National Institute of Respiratory Diseases Ismael Cosio Villegas, Mexico City, Mexico
2 Graduate Program in Biological Sciences, National Autonomous University of Mexico, Mexico City, Mexico

A — research concept and design; B — collection and/or assembly of data; C — data analysis and interpretation; D — writing the article; E — critical revision of the article; F — final approval of the article

Abstract

Asthma and chronic obstructive pulmonary disease (COPD) are widely documented diseases with an inflammatory component. Asthma is a heterogeneous disorder of the airways that involves chronic inflammation, decline of the airway function and tissue remodeling. Chronic obstructive pulmonary disease is a preventable and treatable disease, which is characterized by persistent limited airflow, and is usually progressive with an increased inflammatory response in the airways. The inflammatory response is evoked by the stimulus of noxious particles and gases. Inflammation is a natural process in response to injury, but in asthma and COPD patients it occurs as an abnormal immune response to pathogenic stimuli which induce chronic inflammation, a key process in the pathogenesis of both diseases. However, the inflammatory process is different in both diseases, and is involved in several release patterns of inflammation mediators. It is not entirely clear whether these proteins are simply markers of the inflammatory process that accompanies a chronic disease or if they play a major role in the pathogenesis of the disease. The main proteins which have been described in these illnesses are: IL-4, IL-6, IL-8, and TNF-α. In addition, polymorphisms have been described in genes encoding these proteins that alter the transcription and susceptibility associated with these diseases. In this review, we will focus on asthma and COPD, and the involvement of these proteins and their genetic polymorphisms.

Key words: asthma, COPD, gene regulation, SNP, TNF-α
Background

Inflammation is a common process in chronic respiratory diseases. The presence of increased levels of systemic inflammatory markers is a recurrent finding in laboratory tests. In particular, asthma and chronic obstructive pulmonary disease (COPD) are diseases with a widely documented inflammatory component and have been discussed in various studies; however, given the transversal nature of most of the studies conducted so far and the possible confusion regarding a number of external factors related to lifestyle associated with levels of inflammatory biomarkers, which in turn, are generally nonspecific, it is not entirely clear whether these proteins are simply markers of the inflammatory process that accompanies a chronic disease or if they play a major role in the pathogenesis of the disease. In this review, we will focus on asthma and COPD as study models.

Asthma

Asthma is a heterogeneous disorder of the airways that involves chronic inflammation, decline of the airway function and tissue remodeling.\(^1\) The overall prevalence varies between 1% and 18% of the population in different latitudes.\(^2\) In developed countries, asthma is found in about 10% of adults, while in emerging countries, the prevalence is lower, but rapidly increasing, most likely due to under-diagnosis. The World Health Organization (WHO) estimates that 300 million people worldwide are affected by the disorder and this number is estimated to increase to 400 million by 2025.\(^3\) Although there are no specific genetic or environmental factors conclusive, genetic predisposition to increased immunoglobulin E (IgE) in local mucosa (atopy) is a strong risk factor for developing the disease.\(^4,5\) It has been proposed that asthma develops from a complex interplay between genetic and environmental factors, such as the dose of allergens and respiratory tract infections.\(^4\) This culminates with an abnormal inflammatory response directed by Th2 cells to normally innocuous allergen content in the air.\(^6\)

Chronic asthma immunopathogenesis

Inflammation is a natural process in response to injury, but it occurs in asthmatic patients as an abnormal immune response to pathogenic stimuli which induces chronic inflammation, a key process in the pathogenesis of the disease.\(^7\) Another crucial event in the development of asthma is the recruitment of leukocytes mediated by chemokines, which produce an inappropriate immune activation, believed to be in part responsible for the chronic allergic asthma.\(^8\) In chronic asthma there is an accumulation of CD4 + T cells in airway.\(^9\) These cells typically exhibit an immune response called Th2 cytokine profile characterized by the production of interleukins (IL): IL-4, IL-5 and IL-13, which contribute to the recruitment of eosinophils and the development of airway hyperresponsiveness.\(^10–12\) Moreover, in recent years research has suggested the involvement of Th17 cells, which secrete IL-17A, believed to contribute to the pathogenesis of the disease, however, its mechanism remains obscure.\(^13\)

The initiation of the allergic response in the airways begins with epithelial cells, which release thymic stromal lymphopoietin (TSLP), IL-33 and IL-25 in response to allergens. TSLP regulate the migration of dendritic cells (DCs), present antigen and promote Th cell differentiation. Th cells mediate the IgE isotype switching in B cells. The antigen-specific IgE response leads to the recruitment of mast cells and basophils into the airways, increasing the local allergic response. Additionally, IL-33 and IL-25 induce the release of IL-13 and IL-5 from CD25 + Th cells into the airway, which promotes Th2 cells differentiation and local production of cytokines, such as IL-4, IL-5 and IL-13.\(^14\) In this process, B-cells and memory T cells are generated, which facilitates a faster response to repeated stimulation, thereby causing the chronicity of the disease.\(^15\) Knowledge of asthma molecular phenotypes and the molecular pathways involved in asthma, in particular cytokines which are involved in them, has allowed us to create subgroups of asthma patients based on the activity (or inactivity) of specific cytokine pathways. There have been several studies of gene expression based on the fact that epithelial cells respond to stimuli of various cytokines and they found various overexpressed genes. The calcium-activated chloride channel accessory 1 (CLCA1), peristin (POSTN), serpine peptidase inhibitor (SERPINB3), are all involved in the regulation of IL-13 and IL-4, and therefore Th2 inflammation.\(^16,17\) Other genes that have been found over-expressed in asthmatic patients are ACACA, TPSABI and proteins which are secreted by mast cells. These cells have been implicated in airway hyperresponsiveness, although it has been reported that this is a variable in asthmatic patients.\(^18,19\) The stimulation of bronchial epithelial cells with IL-13 induces the expression of stem cell factor, which is a growth factor and a mast cell attractant. This induction of stem cell factor provides a mechanism for increasing the number of intraepithelial mast cells, which are of particular importance in severe asthma.\(^20\) Genetic polymorphisms in asthma/asthma-like diseases may increase the risk for developing these diseases that are determined by environmental factors. In fact, twin studies have estimated heritability ranging from 35–90%.\(^21\) Different genome-wide association studies (GWAS) have found different genes related to the development and phenotypic features of the disease, as ORM1-like 3, PDE4D (phosphodiesterase 4D, cAMP-specific), IL-1RL1 (interleukin-1 receptor-like 1), IL-18R1 (interleukin-18 receptor 1), HLA-DQ, IL33, SMAD3 (SMAD family member 3), and IL-2RB (interleukin-2 receptor beta).\(^22–24\) Moreover, through genetic association studies and family-based
information, in certain specific protein coding genes it was identified that single nucleotide polymorphisms (SNP) are related to the development of asthma or phenotypes responding to treatment differently. Among them, human leukocyte antigen (HLA), T-cell receptor (TCR), and cytotoxic T-lymphocyte-associated antigen (CTLA-4) may be mentioned. Additionally, genetic variations have been found in genes that encode proteins involved in the inflammatory process, as IL-4, -9, -13, and their respective receptors and intracellular signaling molecules, such as signal transducer and activator of transcription (STAT-6), suppressor of cytokine signaling (SOCS-1).26 Although many of these findings have been replicated in other populations, some of the studies failed to replicate the same results. This is of vital importance because the studies replicate different polymorphisms (within the same chromosome) forming haplotypes and how they contribute to or elucidate a set of genes that may be involved in the development and the progression of the disease.

**Chronic obstructive pulmonary disease**

Chronic obstructive pulmonary disease (COPD) is defined by the Global Initiative for Obstructive Lung Disease (GOLD) as a preventable and treatable disease, which is characterized by persistent limited airflow, which is usually progressive with an increased inflammatory response in the airways, the response is to the stimulus of particles and gases. Exacerbations and co-morbidities contribute to the individual illness severity (GOLD 2011). Cigarette smoking is the major environmental risk factor for COPD, and is more common in men than in women in the case of exposure to cigarette smoke. The Latin American Project for the Investigation of Obstructive Lung Disease (PLATINO) obstructive pulmonary research, conducted by the Latin American Thoracic Association (ALAT), determined the prevalence of COPD in 5 Latin American countries and found that the percentages vary between countries from 7.8% in Mexico City to 17% in Montevideo.30

**Inflammation in COPD**

COPD is a condition characterized by inflammation and airway remodeling, as well as inflammation and the destruction of lung parenchyma, resulting in the obstruction of expiratory airflow, lung hyperinflation, loss of elasticity, and finally altered gas exchange. Lung remodeling and tissue damage coupled with wall thickening, inflammation and fibrosis of the small airways seem to play an important role in the pathogenesis of COPD.31 Pulmonary parenchymal inflammation, oxidative stress, apoptosis, and proteolysis eventually result in emphysematous destruction of the alveolar wall.32

**Inflammatory mediators involved in COPD**

The family of proteins known as chemokines and chemokine receptors is considered to be key mediators in inflammatory cell recruitment. Chemokine receptors play an important role in the trafficking of immune cells to sites of injury and inflammation after an antigen encounter. Approximately, 50 chemokines and their 20 receptors have been associated with COPD. Among its functions is the ability to drive the migration of leukocytes involved in proliferation, differentiation, survival, and cellular retention.33 In addition, chemokine receptors 5 (CCR5) and 3 (CCR3) have been implicated in COPD, since the expression of these receptors on T cells infiltrated in COPD patients has been demonstrated. IL-8, growth related oncogene (GRO-alpha), and extractable nuclear antigen (ENA)-78 may be involved in the increased numbers of PMN in smokers’ airspaces, whereas greater concentrations of macrophages, neutrophils, IL-1β and IL-8 are elevated in the pulmonary microenvironment of smokers in a cigarette dose-dependent manner.35,36 IL-8 is a potent neutrophil chemoattractant found in elevated levels of this cytokine in induced sputum of COPD patients and was correlated with a high number of neutrophils.37,38 Concentrations of IL-8 are even higher in emphysema patients, where there is a-1 antitrypsin deficiency.39

Inhibitory cytokines, including IL-10, transforming growth factor β1 (TGF-β1), IL-11, and the receptor antagonist of IL-1 are also delivered to limit the duration and extent of the inflammatory response in the lung of patients with COPD, but there is limited information. IL-10 is particularly useful as an inhibitor of various inflammatory processes, low levels of IL-10 positive cells in sputum of COPD patients have been reported.36

**Genetic polymorphisms associated with COPD**

As mentioned previously, COPD is characterized by chronic inflammation based on an abnormal inflammatory response. Studies found different polymorphisms in genes encoding inflammatory mediators that have been implicated in the pathogenesis of the disease, such as tumor necrosis factor (TNF), IL-8 and TGF β, and others. Regarding the TNF gene, as previously described, one SNP in the promoter region of the gene, which has been identified directly, affects the transcriptional regulation of the same.40 Studies show some relevance to the SNP-308GA/TNF in the Asian populations but not in Caucasian populations; for example, Japanese and Taiwanese populations show an increased prevalence of COPD in relation to their respective control groups, but these results have
not been confirmed in other populations. Recent studies have shown a relationship between metabolic alterations and changes in the levels of TNF-α in the systemic circulation of patients with COPD, where TNF-α is associated with accelerated metabolism and protein loss of skeletal muscle and adipose tissue. Moreover, IL-8 is a chemokine which mediates the activation and migration of neutrophils from peripheral blood to tissue. This plays an important role in initiating the amplification of the inflammatory response. A transversion (A→G) at position -351 of the promoter of IL-8 has been positively associated with bronchiolitis reported, but inversely associated with bronchial asthma. There are many genetic association studies of polymorphisms in genes whose protein products are involved in the inflammatory process, although their participation in the disease is not clear. Table 1 summarizes the main findings in COPD and in asthma.

Major inflammatory mediators and regulatory processes

A number of polymorphisms in genes encoding key proteins in the inflammatory process are found in promoter regions, including IL4, IL6, IL8 and TNF, to name a few, so that it is important to meet regulatory aspects of these genes and their relationship to the pathologies in question. IL4 is a glycoprotein of molecular weight approximately 15 kDa. Its expression is restricted to activated T cells, mast cells, basophils and eosinophils. The IL-4 was discovered as a cofactor in the proliferation of resting B cells stimulated with anti-IgM. IL-4 acts as a differentiation factor for B lymphocytes by regulating the IgG4 isotype switching to IgE and induces an increased expression of major histocompatibility complex class II (MHC II). It also promotes Th2 differentiation from Th0 cells, stimulates their growth and proliferation and inhibits the development of Th1 cells. IL-4 is shown to be increased in bronchoalveolar lavage (BAL) fluid and serum of allergic patients. People with atopy have altered regulation of the production of IL-4 in response to bacterial antigens and dust mites. Furthermore, atopic patients have a higher number of T cells secreting IL-4 compared with normal subjects. It also increases the release of chemokines such as CCL11 and expression of adhesion molecules such as VCAM-1 on lung fibroblasts, thereby promoting swelling of the airway, and inhibits the apoptosis of eosinophils and Th2 lymphocytes by expression of the Bcl-2 protein. The findings and potential roles in COPD are still unknown, although there are some reports of increased serum levels in relation to the degree of smoking, but these findings were found in African population and not replicated in Mexican mestizo population.

Gene structure and regulation of expression of IL-4

IL4 gene consists of 4 exons and 3 introns, located on the long arm of chromosome 5 in cytogenetic bands q23–31; it has potential binding sites for several transcription factors with positive or negative regulatory sequences, depending on the action generated after transcription factor binding. Among the main factors that interact with positive regulatory sequences are POS-1 and POS-2, which need to be assembled and which need to interact with different transcription factors such as C/EBP-γ, NF-IL6, NF-IL6/3, Jun or NF-AT, depending on the cellular expression.

IL-6

This is a pleiotropic cytokine that plays an important role in regulating the immune and inflammatory response. It is produced by T cells, monocytes, fibroblasts, endothelial cells and keratinocytes. It also stimulates B cell differentiation and antibody production in synergy with IL-3 in the development of megakaryocytes and platelet production. It induces the expression of hepatic acute phase protein and has been associated with impaired functional capacity, reduced the daily physical activity and general deterioration of the health status. Before the nomenclature of IL-6, it was known in a variety of names, such

<table>
<thead>
<tr>
<th>Protein</th>
<th>COPD</th>
<th>Asthma</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-4</td>
<td>no studies</td>
<td>SNP associated with allergic rhinitis, serum levels and induced sputum ↑↑</td>
<td>47, 48</td>
</tr>
<tr>
<td>IL-6</td>
<td>IL-6 ↑↑↑ in induced sputum, BAL, and exhaled air concentration during exacerbations, SNPs associated with COPD</td>
<td>serum levels and BAL ↑↑↑ in patients with no allergic asthma</td>
<td>49–52, 54–56</td>
</tr>
<tr>
<td>IL-8</td>
<td>serum levels and induced sputum ↑↑↑, several SNPs associated with COPD</td>
<td>levels ↑↑↑ in BAL, in asthmatic patients with C. pneumoniae infection</td>
<td>37, 38, 57–59</td>
</tr>
<tr>
<td>TNF-α</td>
<td>serum levels and induced sputum ↑↑↑, SNPs associated with COPD and clinic phenotypes</td>
<td>↑↑↑ miRNAs involved in TNF regulation, serum levels ↑↑↑ in asthmatic patients without eosinophils</td>
<td>31, 41, 60–67</td>
</tr>
</tbody>
</table>

↑↑↑ – raised; BAL – bronchoalveolar lavage; SNP – single nucleotide polymorphism; miRNA – microRNA.
as IFN-b2, T cell replacement factor (TFR), B-cell differentiation factor (BCDF), B-cell stimulating factor, and hybridoma plasmacytoma growth (HPGF or IL-HPI). In relation to their association with disease, asthma patients showed elevated serum levels of IL-6 and of bronchoalveolar lavage fluid, compared with nonsmokers with asthma whose results were as stable as non-asthmatics. Additionally, a study conducted by Neveu et al. in 2010 showed an increase in levels of IL-6 and IL-13 in sputum from patients with allergic asthma; interestingly IL-1β and TNF-α were not increased, which suggests an increase in IL-6 independent of the degree of inflammation. In COPD, increased IL-6 concentrations are found in induced sputum, bronchoalveolar lavage and concentrated exhaled air from COPD patients, particularly during exacerbations. IL-6 is also increased in plasma during exacerbations. There is genetic evidence regarding the involvement of certain IL-6 gene polymorphisms SNPs type involved in the increased production of the protein and its association with phenotypic traits, in both asthma and COPD.

**Gene structure and regulation of expression of IL-6**

IL-6 gene is about 5 kb and consists of 4 exons and 6 introns, and is located on the short arm of chromosome 7 in the region p15–21. The expression control depends on several different stimuli and cellular mechanisms that can act individually or in concert to activate transcription. The first to be shown to induce the production of IL-6 are the phorbol ester, IL-1 and TNF-α. Within the promoter region of IL6, there are regions of the target signal transduction. These targets include DNA binding regions which are specific for nuclear factors such as NFIL-6 (protein binding CCAAT elements), nuclear factor kappa light chain in B cells (NFkB), activator protein-1 (AP-1), protein binding cAMP response element (CREB), and glucocorticoid receptor (GR), these sequences can be found at 200bp upstream of the transcription start site.

**IL-8**

IL-8 is a chemokine, a member of the CXC family, which is produced by macrophages, epithelial cells and fibroblasts in response to bacterial or viral stimulation or cellular stress response. It has been involved in the development of various biological processes such as repair, angiogenesis and inflammation. Its main function is the chemotaxis of neutrophils and lymphocytes; it exerts its biological activity through 2 high affinity receptors designated as CXCR1 and CXCR2. Regarding the association of this chemokine with COPD, its function is still unknown, although studies of both genetic association and/or serum levels with this disease have been established. For example, Yamamoto et al. also reported elevated concentrations in sputum in COPD patients compared to different control groups. Consistent with this finding, Keatings et al. described elevated IL-8 in induced sputum of COPD patients compared to different control groups. Jeremy Hull et al. found polymorphism associated with bronchiolitis IL-8–251A in a family study conducted in the UK. Yet, there are no studies that prove the role of these polymorphisms in this disease. Recently, Alfredo de Diego et al. conducted a study in Valencia, Spain, in which the values determined in sputum of different cytokines, including IL-8, resulting in such high values. Additionally, cultured bronchial epithelial cells, which were stimulated with cigarette smoke extract, for the purpose of measuring mRNA levels, resulted in an increased amount of mRNA and TNF-α, IL-8, which suggests that these molecules may increase in COPD, in response to the stimulus of cigarette smoke. Regarding the most important findings of IL-8 and asthma, the findings are limited; however, in 2010, Patel et al. found an increase in bronchoalveolar lavage IL8 mRNA in asthmatic patients with C. pneumoniae. No results are available on polymorphisms in IL-8 gene with asthma.

**Gene structure and regulation of expression of IL8**

IL-8 gene consists of 4 exons and 3 introns, with a total length of 5.25 kb, and is located on the long arm of chromosome 4 in the region (q12–21). The 5' flanking region contains several IL-8 gene regulatory elements, e.g., binding sites for transcription factors such as NF-kB, NF-IL6, AP-1, AP-2, AP-3, interferon regulatory factor-1 (IRF-1) and glucocorticoid response elements (GRE). Transcriptional activation can occur after the stimulation with IL-1α IL-1β, TNF-α, bacterial endotoxin, reactive oxygen species and nitrogen intermediates. IL-8 can also be regulated at a post-transcriptional level, because in the 3' flanking region contains a repeat motif ATTTA, which is responsible for mRNA destabilization of several different cytokines. TNF-α is the primary mediator of the immune response to gram-negative bacteria and other infectious organisms. The release of TNFα produced the local activation of vascular endothelium, with a release of nitric oxide, vasodilation and increased vascular permeability, leading to the recruitment of inflammatory cells, immunoglobulins and complement, causing the activation of T and B lymphocytes. It also increases adhesion and platelet activation. Tumor necrosis factor alpha is a critical molecule in the regulation of inflammation, inducing a cascade of other inflammatory cytokines, chemokines and growth factors. The results of several studies in vivo and in vitro indicate that the increased production of TNF-α leads to an increase in inflammation.
and pro-oxidative response. TNF-α mediates inflammation and is thought to play a key role in respiratory and systemic features of COPD. Jardim et al. found increased expression of the miRNAs involved in the regulation of TNF, IL-8 and COX2 in epithelial cells of asthmatic patients. In another study, Waserman et al. found an increase in serum levels of Th1-type cytokines, including TNF-α, in asthmatic patients without eosinophilia. A result which correlates with these findings on this molecule has been described previously. With respect to TNF-α and its association with COPD in 2010, Tanni et al. conducted a study that showed high serum levels of TNF-α in patients with COPD and healthy chronic smokers compared with nonsmokers. In another study, Gan et al. found elevated levels of TNF-α in bronchoalveolar lavage and induced sputum of COPD patients compared to the control group.

Genetic association studies of TNF in COPD show some significance for rs1800629 (position -308 G/A) in Asian populations, but not in Caucasian populations. However, these results are contradictory, because they could not be confirmed in other populations. In 2012, a study was conducted in the Taiwanese population, which identified TNF-863 (rs1800630) with an improvement in FEV1/FVC and with increasing BMI. Another gene that affects the expression of TNF-α is lymphotixin alpha gene (LTA). The rs909253 (G→A) in LTA has been implicated in gene regulation and reported associations with asthma and COPD. Elevated serum TNF-α levels have been associated with SNPs in LTA.

### Structure and regulation of gene expression of TNF

TNF gene was cloned in 1984 and mapped along with the major histocompatibility complex on chromosome 6p21.3, along with genes encoding LT-a and LT-b. The TNF gene consists of 4 exons and 3 introns, of which the last exon encodes over 80% of the secreted protein. The major regulatory gene elements of TNF are the elements of response to NFkB important factor involved in LPS conferred inducibility. However, many other factors may be involved in the selective activation and expression of TNF. The mRNAs of TNF and LT, like many other cytokines, have AU-rich sequences in the 3'UTR region of the mRNA, which decreases its stability. These sequences represent recognition sites for specific mRNA processing proteins. In 1988, Beutler et al. identified a ribonuclease that was isolated from mouse macrophages, which specifically destabilizes mRNA containing the sequence UAUAUAUAU in the 3'UTR. Interestingly, LT mRNA lacks these AU regions. Additionally, TNF-α induces several proteins involved in inflammation, tissue repair, hematopoiesis, immune response and anti-tumor effects. Some of these genes encode proteins called “TNF resistance proteins” which may inhibit TNF cytotoxicity. Examples of these proteins include superoxide dismutase, protein A-20 zinc finger and the heat shock protein-70 (HSP70).

### Conclusions

Asthma and COPD are lung diseases, which represent a major public health problem and our country is no exception. Both disease entities share a common mechanism to inflammation, which acts differently in both pathologies. In this regard, there are several studies that have explored the levels of proteins involved in inflammation, both systemically and locally. According to these results, we can see that there are mediators that are shared in both diseases, such as IL1β, IL-6 and TNF-α, plus some others which differ, such as IL13, IL-4, IL-5, and IL-8. For this reason, to understand the regulatory mechanisms that lead to the expression of these gene products as well as the research studies which analyze the genetic variations and their relationship with the phenotype expressed, it is vital to differentiate the genetic and molecular mechanism of both illnesses and to provide more effective treatment alternatives that contribute to the improvement of the patient.

### Table 2. Polymorphisms in genes associated to inflammation and its biological implication

<table>
<thead>
<tr>
<th>Gene</th>
<th>Polymorphism</th>
<th>Change</th>
<th>Biological implication</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNF</td>
<td>rs1800629</td>
<td>-308</td>
<td>G→A</td>
<td>increases transcription and protein levels</td>
</tr>
<tr>
<td></td>
<td>rs361525</td>
<td>-238</td>
<td>G→A</td>
<td>increases transcription</td>
</tr>
<tr>
<td></td>
<td>rs1800630</td>
<td>-863</td>
<td>C→A</td>
<td>decreased binding capacity of NFkB</td>
</tr>
<tr>
<td>IL-4</td>
<td>rs2243250</td>
<td>-589</td>
<td>C→T</td>
<td>increases transcriptional activity</td>
</tr>
<tr>
<td></td>
<td>rs2070874</td>
<td>-33</td>
<td>C→T</td>
<td>increases the amount of protein</td>
</tr>
<tr>
<td>IL-6</td>
<td>rs1800795</td>
<td>-174</td>
<td>G→C</td>
<td>increased plasma levels</td>
</tr>
<tr>
<td></td>
<td>G/G/A</td>
<td>-174/-572/-597</td>
<td>GG/G/A</td>
<td>haplotype associated with increased mRNA</td>
</tr>
</tbody>
</table>

| IL-8 | rs4073       | -251   | A→T                   | increases the protein expression up to 5 folds | 44, 117 |


54. Bucchioni E, Kharitonov SA, Allegra L, Barnes PJ. High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. Respir Med. 2003;97:1299–1302.


